Publications
Detailed Information
Performance Evaluation of Affinity Column Mediated Immunometric Assay for Tacrolimus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Jae-Woo | - |
dc.contributor.author | An, Dongheui | - |
dc.contributor.author | Song, Junghan | - |
dc.contributor.author | Chung, Hee-Jung | - |
dc.contributor.author | Lee, Woochang | - |
dc.contributor.author | Min, Won-Ki | - |
dc.contributor.author | Chun, Sail | - |
dc.contributor.author | Park, Hae-Il | - |
dc.date.accessioned | 2012-05-23T01:45:20Z | - |
dc.date.available | 2012-05-23T01:45:20Z | - |
dc.date.issued | 2009-10 | - |
dc.identifier.citation | KOREAN JOURNAL OF LABORATORY MEDICINE; Vol.29 5; 415-422 | ko_KR |
dc.identifier.issn | 1598-6535 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76298 | - |
dc.description.abstract | Background : Therapeutic drug monitoring (TDM) of tacrolimus is essential because of narrow therapeutic range and poor correlation of dose to blood concentration. Affinity Column Mediated Immunometric Assay (ACMIA) does not require a pretreatment steps in measurement of tacrolimus. In this study, we evaluated the performance of tacrolimus assay using ACMIA (Dimension RxL Max, Dade Behring). Methods : The imprecision, the linearity and the detection limits and the interferences by bilirubin and chyle, and correlation with hematocrit for tacrolimus by ACMIA were evaluated according to Clinical and Laboratory Standards Institute guidelines EP5-A2, EP6-A, EP17-A, EP9-A2, and EP7-A2. Method comparison studies with microparticle enzyme immunoassay (MEIA) (IMx Tacrolimus 11, Abbott Laboratories) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Waters 2795 Quattromicro API, Micromass) were also performed. Results: The total imprecision for low, middle and high level was 12.8%, 9.0% and 6.7%, respectively. The range of tacrolimus from 3.1 ng/mL to 35.4 ng/mL showed a clinically relevant linearity. The limit of detection and the functional sensitivity were 0.24 ng/mL and 0.72 ng/mL, respectively. Tacrolimus concentration measurement (Tac-CM) with ACMIA did not show significant interferences with bile and chyle and also did not show significant correlation with hematocrit. In comparison study for Tac-CM with MEIA and LC-MS/MS, Tac-CM with ACMIA showed a good correlation with MEIA (r=0.950) and LC-MS/MS (r=0.946). Conclusions : The imprecision, linearity, detection limits, interference and correlation of Tac-CM with ACMIA were suitable for clinical use. Tac-CM with ACMIA could reduce turn around time and help clinicians to manage transplant patients on immunosuppressant therapy. (Korean J Lab Med 2009;29:415-22) | ko_KR |
dc.language.iso | ko | - |
dc.publisher | KOREAN SOC LABORATORY MEDICINE | ko_KR |
dc.subject | Tacrolimus | ko_KR |
dc.subject | Affinity column mediated immunometric assay | ko_KR |
dc.subject | Therapeutic drug monitoring | ko_KR |
dc.title | Performance Evaluation of Affinity Column Mediated Immunometric Assay for Tacrolimus | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 정재우 | - |
dc.contributor.AlternativeAuthor | 안동휘 | - |
dc.contributor.AlternativeAuthor | 송정한 | - |
dc.contributor.AlternativeAuthor | 정희정 | - |
dc.contributor.AlternativeAuthor | 박해일 | - |
dc.contributor.AlternativeAuthor | 이우창 | - |
dc.contributor.AlternativeAuthor | 전사일 | - |
dc.contributor.AlternativeAuthor | 민원기 | - |
dc.identifier.doi | 10.3343/kjlm.2009.29.5.415 | - |
dc.citation.journaltitle | KOREAN JOURNAL OF LABORATORY MEDICINE | - |
dc.description.citedreference | Dorizzi RM, 2008, CLIN CHIM ACTA, V387, P177, DOI 10.1016/j.cca.2007.08.005 | - |
dc.description.citedreference | Westley IS, 2007, THER DRUG MONIT, V29, P584 | - |
dc.description.citedreference | Griffey MA, 2007, CLIN CHIM ACTA, V384, P48, DOI 10.1016/j.cca.2007.05.019 | - |
dc.description.citedreference | *AACC CAP, 2007, CSM B SURV IMM DRUGS | - |
dc.description.citedreference | *AACC CAP, 2007, CSM A SURV IMM DRUGS | - |
dc.description.citedreference | KIM JH, 2007, J LAB MED QUAL ASSUR, V29, P121 | - |
dc.description.citedreference | Napoli KL, 2006, THER DRUG MONIT, V28, P491 | - |
dc.description.citedreference | Tomita T, 2005, THER DRUG MONIT, V27, P94 | - |
dc.description.citedreference | *CLIN LAB STAND I, 2005, EP7A2 CLIN LAB STAND | - |
dc.description.citedreference | LeGatt DF, 2004, CLIN BIOCHEM, V37, P1022, DOI 10.1016/j.clinbiochem.2004.08.004 | - |
dc.description.citedreference | *CLIN LAB STAND I, 2004, EP5A2 CLIN LAB STAND | - |
dc.description.citedreference | *CLIN LAB STAND I, 2004, EP17A CLIN LAB STAND | - |
dc.description.citedreference | Taylor PJ, 2003, THER DRUG MONIT, V25, P259 | - |
dc.description.citedreference | Ghoshal AK, 2003, CLIN CHIM ACTA, V331, P135, DOI 10.1016/S0009-8981(03)00114-1 | - |
dc.description.citedreference | *CLIN LAB STAND I, 2003, EP6A CLIN LAB STAND | - |
dc.description.citedreference | Keown PA, 2002, CURR OPIN NEPHROL HY, V11, P619, DOI 10.1097/01.mnh.0000040047.33359.86 | - |
dc.description.citedreference | Kuzuya T, 2002, THER DRUG MONIT, V24, P507 | - |
dc.description.citedreference | Ghoshal AK, 2002, CLIN BIOCHEM, V35, P389 | - |
dc.description.citedreference | *CLIN LAB STAND I, 2002, EP9A2 CLIN LAB STAND | - |
dc.description.citedreference | Kroll MH, 2000, ARCH PATHOL LAB MED, V124, P1331 | - |
dc.description.citedreference | Cogill JL, 1998, CLIN CHEM, V44, P1942 | - |
dc.description.citedreference | JUSKO WJ, 1995, THER DRUG MONIT, V17, P606 | - |
dc.description.citedreference | IWASAKI K, 1995, DRUG METAB DISPOS, V23, P28 | - |
dc.description.citedreference | NAKAGAWA H, 1994, LANCET, V344, P883 | - |
dc.description.citedreference | PETERS DH, 1993, DRUGS, V46, P746 | - |
dc.description.citedreference | WESTGARD JO, METHOD VALIDATION | - |
dc.description.citedreference | *US FDA, GUID IND BIO METH VA | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.